Behavioral Therapy in Combination with Pharmacotherapy



Behavioral treatments (BT) are a group of therapies that aim to improve overactive bladder symptoms by modifying patient behavior or his/her environment. They may include bladder diary, timed voiding, delayed voiding, pelvic floor muscle training, urge suppression, biofeedback, electrical stimulation, fluid management, dietary changes, weight loss, and other lifestyle changes. Guidelines designate BT as first-line treatments because they are as effective in improving symptoms as pharmacological treatment and are relatively noninvasive and rarely associated with adverse events. However, they demand active participation of the patient as well as time and effort from the clinician. Behavioral and drug therapies are frequently used in combination in clinical practice to enhance patient symptom control and quality of life. A number of studies indicate that starting behavioral and pharmacological therapy simultaneously may improve outcomes. Alternatively, patients who are not significantly improved on behavioral or drug therapy alone may benefit from adding the alternate therapy in a stepped approach. In this chapter we review the use of behavioral therapy in combination with pharmacotherapy for the treatment of non-neurogenic overactive bladder.


Overactive bladder Management Muscarinic antagonists Behavioral treatment Multimodal therapy 


  1. 1.
    Dumoulin C, Adewuyi T, Booth J, Bradley C, Burgio K, Hagen S, Hunter K, et al. Adult conservative management. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. International consultation on incontinence. 6th ed. 6th International Consultation on Incontinence, Tokyo, September 2016. pp. 1443–628. Bristol: The International Continence Society (ICS) and the International Consultation on Urological Diseases (ICUD); 2017.Google Scholar
  2. 2.
    Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142–E73.CrossRefGoogle Scholar
  3. 3.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. 2012; amended 2014. Accessed 27 Apr 2018.
  4. 4.
    Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.CrossRefGoogle Scholar
  5. 5.
    Burkhard FC, Bosch, JLHR, Cruz F, Lemack GE, Nambiar N, Thiruchelvam A, et al. EAU guidelines on urinary incontinence in adults. Arnhem: EAU Guidelines Office; 2017. Accessed 26 Apr 2018.
  6. 6.
    Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.CrossRefGoogle Scholar
  7. 7.
    Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.CrossRefGoogle Scholar
  8. 8.
    Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) trial. J Am Geriatr Soc. 2011;59(12):2209–16.CrossRefGoogle Scholar
  9. 9.
    Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50(5):808–16.CrossRefGoogle Scholar
  10. 10.
    Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.PubMedGoogle Scholar
  11. 11.
    Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25(4):327–38.CrossRefGoogle Scholar
  12. 12.
    Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008;149(3):161–9.CrossRefGoogle Scholar
  13. 13.
    Mattiasson A, Masala A, Morton R, Bolodeoku J, Group SS. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. BJU Int. 2010;105(8):1126–35.CrossRefGoogle Scholar
  14. 14.
    Mattiasson A, Blaakaer J, Hoye K, Wein AJ, Tolterodine Scandinavian Study G. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91(1):54–60.CrossRefGoogle Scholar
  15. 15.
    Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48(4):370–4.CrossRefGoogle Scholar
  16. 16.
    Borello-France D, Burgio KL, Goode PS, Markland AD, Kenton K, Balasubramanyam A, et al. Adherence to behavioral interventions for urge incontinence when combined with drug therapy: adherence rates, barriers, and predictors. Phys Ther. 2010;90(10):1493–505.CrossRefGoogle Scholar
  17. 17.
    Wein AJ. Diagnosis and treatment of the overactive bladder. Urology. 2003;62(5 Suppl 2):20–7.CrossRefGoogle Scholar
  18. 18.
    Elser DM, Wyman JF, McClish DK, Robinson D, Fantl JA, Bump RC. The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence. Continence Program for Women Research Group. Neurourol Urodyn. 1999;18(5):427–36.CrossRefGoogle Scholar
  19. 19.
    Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM 2nd, Redden DT. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol. 2010;184(2):598–603.CrossRefGoogle Scholar
  20. 20.
    Millard RJ; Asia Pacific Tolterodine Study G. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn. 2004;23(1):48–53.Google Scholar
  21. 21.
    Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol. 1997;4(2):111–25.CrossRefGoogle Scholar
  22. 22.
    Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32(1):11–8.CrossRefGoogle Scholar
  23. 23.
    Bristow SE, Hasan ST, Neal DE. TENS: a treatment option for bladder dysfunction. Int Urogynecol J Pelvic Floor Dysfunct. 1996;7(4):185–90.CrossRefGoogle Scholar
  24. 24.
    Vandoninck V, van Balken MR, Finazzi AE, Petta F, Micali F, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 2003;22(3):227–32.CrossRefGoogle Scholar
  25. 25.
    Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16.CrossRefGoogle Scholar
  26. 26.
    Amend B, Matzel KE, Abrams P, de Groat WC, Sievert KD. How does neuromodulation work. Neurourol Urodyn. 2011;30(5):762–5.CrossRefGoogle Scholar
  27. 27.
    Van Kerrebroeck PE, Marcelissen TA. Sacral neuromodulation for lower urinary tract dysfunction. World J Urol. 2012;30(4):445–50.CrossRefGoogle Scholar
  28. 28.
    Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu Ercan C, et al. The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. Gynecol Endocrinol. 2010;26(10):729–32.CrossRefGoogle Scholar
  29. 29.
    Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32(1):179–84.CrossRefGoogle Scholar
  30. 30.
    Cao Y, Lv J, Zhao C, Li J, Leng J. Cholinergic antagonists combined with electrical stimulation or bladder training treatments for overactive bladder in female adults: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2016;36(10):801–8.CrossRefGoogle Scholar
  31. 31.
    Abulseoud A, Moussa A, Abdelfattah G, Ibrahim I, Saba E, Hassouna M. Transcutaneous posterior tibial nerve electrostimulation with low dose trospium chloride: could it be used as a second line treatment of overactive bladder in females. Neurourol Urodyn. 2018;37(22):842–8.CrossRefGoogle Scholar
  32. 32.
    Andersson KE, Cardozo L, Cruz F, Lee K-S, Suhai A, Wein AJ. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th International Consultation on Incontinence, Tokyo, September 2016, pp. 805–957. The International Continence Society (ICS) and the International Consultation on Urological Diseases (ICUD); 2017.Google Scholar
  33. 33.
    Hextall A. Oestrogens and lower urinary tract function. Maturitas. 2000;36(2):83–92.CrossRefGoogle Scholar
  34. 34.
    Cardozo L, Rekers H, Tapp A, Barnick C, Shepherd A, Schussler B, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47–53.CrossRefGoogle Scholar
  35. 35.
    Rufford J, Hextall A, Cardozo L, Khullar V. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(2):78–83.CrossRefGoogle Scholar
  36. 36.
    Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92(4 Pt 2):722–7.PubMedGoogle Scholar
  37. 37.
    Krause M, Wheeler TL 2nd, Richter HE, Snyder TE. Systemic effects of vaginally administered estrogen therapy: a review. Female Pelvic Med Reconstr Surg. 2010;16(3):188–95.CrossRefGoogle Scholar
  38. 38.
    Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.PubMedGoogle Scholar
  39. 39.
    Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol. 1989;160(1):176–81.CrossRefGoogle Scholar
  40. 40.
    Abdelbary AM, El-Dessoukey AA, Massoud AM, Moussa AS, Zayed AS, Elsheikh MG, et al. Combined vaginal pelvic floor electrical stimulation (PFS) and local vaginal estrogen for treatment of overactive bladder (OAB) in perimenopausal females. Randomized controlled trial (RCT). Urology. 2015;86(3):482–6.CrossRefGoogle Scholar
  41. 41.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65.CrossRefGoogle Scholar
  42. 42.
    Quintiliano F, Veiga ML, Moraes M, Cunha C, de Oliveira LF, Lordelo P, et al. Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial. J Urol. 2015;193(5 Suppl):1749–53.CrossRefGoogle Scholar
  43. 43.
    Borch L, Hagstroem S, Kamperis K, Siggaard CV, Rittig S. Transcutaneous electrical nerve stimulation combined with oxybutynin is superior to monotherapy in children with urge incontinence: a randomized, placebo controlled study. J Urol. 2017;198(2):430–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hospital of the University of Sao Paulo School of MedicineDivision of UrologySao PauloBrazil

Personalised recommendations